*programme subject to change |
07/09/2016 Epidemiology and Public Health | ||||||
8:00 am | Registration Foyer | |||||
9:00 am - 9:10 am | Welcome to the Conference Scandinavia Ballroom Olav Dalgard, Akershus University Hospital, Norway | |||||
9:10 am - 9:15 am | Opening Statement from Community Member Scandinavia Ballroom Ronny Bjørnestad, proLAR, Norway | |||||
9:15 am - 10:40 am | Session A: HCV Epidemiology Scandinavia Ballroom Chairperson: Magdalena Harris, London School of Hygiene and Tropical Medicine Chairperson: Tom Hemming Karlsen, University of Oslo | |||||
9:15 am - 9:35 am | The Burden of HCV Infection Among PWID Scandinavia Ballroom Sharon Hutchinson, Glasgow Caledonian University, United Kingdom Abstract | |||||
9:35 am - 9:55 am | The Natural History of HCV Infection Scandinavia Ballroom Knut Boe Kielland, Innlandet Hospital Trust, Norway Abstract | |||||
9:55 am - 10:10 am | Can Health Risk Behaviours Explain the High Mortality Rate for Adults with Chronic Hepatitis C in the United States? Scandinavia Ballroom Hamish Innes, Glasgow caledonian university Abstract | |||||
10:10 am - 10:25 am | Effect of Combined Harm Reduction Strategies on HCV Primary and Reinfection Incidences among People Who Inject Drugs in Montreal, Canada Scandinavia Ballroom Julie Bruneau, Université de Montréal Abstract | |||||
10:25 am - 10:40 am | The Prison Economy of Needles and Syringes: What Opportunities Exist for Hepatitis C Risk Reduction When Prices are so High? Scandinavia Ballroom Andrew Lloyd, University of New South Wales, Australia Abstract | |||||
10:40 am - 11:00 am | Coffee Break Foyer | |||||
11:00 am - 12:00 pm | Session B: Harm Reduction Scandinavia Ballroom Chairperson: Ronny Bjørnestad, proLAR, Norway Chairperson: Matthew Hickman, University of Bristol, United Kingdom | |||||
11:00 am - 11:20 am | State-of-the-Art Lecture: Opioid and Stimulant Substitution Treatment Scandinavia Ballroom Johan Franck, Karolinska Institutet, Sweden | |||||
11:20 am - 11:40 am | Sharing of Needles, Syringes and Injecting Equipment: Risk of HCV Transmission and Prevention Potential Scandinavia Ballroom Holly Hagan, New York University, United States | |||||
11:40 am - 12:00 pm | Advances and Opportunities for Harm Reduction in Europe Scandinavia Ballroom Mags Maher, EuroNPUD, United Kingdom | |||||
12:00 pm - 1:30 pm | Lunch Restaurant | |||||
12:15 pm - 1:15 pm | Industry Sponsored Symposium Stockholm/Oslo | |||||
1:45 pm - 3:00 pm | Session C Oral Abstracts: Epidemiology and Public Health København Chairperson: Peter Vickerman, University of Bristol, United Kingdom Chairperson: Angella Duvnjak, AIVL, Australia | Session D: Oral Abstracts: Epidemiology and Public Health Stockholm/Oslo Chairperson: Lisa Maher, The Kirby Institute, UNSW Australia | ||||
1:45 pm - 2:00 pm | Hepatitis C and HIV Treatment Cascades among People Who Inject Drugs. Results from a Sero-Behavioural Survey among Current Injectors in Germany København Ruth Zimmermann, Robert Koch Institute Abstract | Molecular Epidemiology of Full-Length Hepatitis C Virus Genomes among Injecting Drug Users with Recent Infection: The Inc3 Study Stockholm/Oslo Chaturaka Rodrigo, University of New South Wales Abstract | ||||
2:00 pm - 2:15 pm | The Role of Incarceration in HCV Transmission amongst People who Inject Drugs: A Modelling Analysis København Jack Stone, University of Bristol Abstract | Liver Disease Burden and Clinical Follow-Up during a Liver Health Promotion Intervention Integrating Non-Invasive Liver Disease Screening in Drug and Alcohol Settings: The Liverlife Study Stockholm/Oslo Jason Grebely, Kirby Institute, UNSW Australia Abstract | ||||
2:15 pm - 2:30 pm | Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting: The HITS-P Study København Evan Cunningham, UNSW Australia Abstract | Successful Model of Testing and Linking People who Inject Drugs (PWID) to Treatment using Direct Acting Antivirals Stockholm/Oslo Nalinikanta Rajkumar, Community Network for Empowerment (CoNE) Abstract | ||||
2:30 pm - 2:45 pm | Hepatitis C Virus Exposure, Infection and Associated Risk Behaviours in Two Maximum-Security Prisons in New South Wales, Australia København Behzad Hajari, The Kirby Institute, UNSW Australia Abstract | Changes in Risk Behaviours during and Following Treatment for Hepatitis C Virus Infection among People Who Inject Drugs: The ACTIVATE Study Stockholm/Oslo Håvard Midgard, Akershus University Hospital Abstract | ||||
2:45 pm - 2:50 pm | Monitoring HCV among People Who Inject Drugs in Europe: A Set of Indicators to Serve Policy and Practice København Isabelle Giraudon, EMCDDA Abstract | Exposure to opioid substitution therapy following hepatitis C notification: Implications for provision of antiviral therapies in drug treatment settings Stockholm/Oslo Sarah Larney, National Drug and Alcohol Research Centre, UNSW Australia Abstract | ||||
2:50 pm - 2:55 pm | Combining the Expansion of Medicated Assisted Therapies and HCV Treatment among PWID in Ukraine: Insights from Network Modeling København Alexei Zelenev, Yale School of Medicine Abstract | Fatigue in Patients with Chronic Hepatitis C: The FAT-HEP Study. A Cross Sectional Study of Fatigue and its Relation to Substance Use and OST Stockholm/Oslo Anne Øvrehus, University of Southern Denmark, Denmark Abstract | ||||
2:55 pm - 3:00 pm | HCV Infection and HIV-HCV Coinfection among "New" Injectors during an HIV Outbreak in Athens, Greece: Results from the Aristotle Programme København Vana Sypsa, National and Kapodestrian University of Athes Abstract | Multi-Disciplinary Managed Care Networks-Lifesaving Interventions for Hepatitis C Patients Stockholm/Oslo John Dillon, University of Dundee Abstract | ||||
3:00 pm - 3:30 pm | Coffee Break Foyer | |||||
3:30 pm - 3:45 pm | Poster Highlights Scandinavia Ballroom Jason Grebely, The Kirby Institute, UNSW, Australia | |||||
3:45 pm - 5:00 pm | Session E: Limiting the HCV Epidemic Scandinavia Ballroom Chairperson: Kimberly Page, University of New Mexico Health Sciences Center, United States Chairperson: Mary Harrod, CEO, NUAA | |||||
3:45 pm - 4:05 pm | State-of-the-Art Lecture: HCV Treatment as Prevention Scandinavia Ballroom Matthew Hickman, University of Bristol, United Kingdom | |||||
4: 05 pm - 4:25 pm | HCV Vaccine Development: Where Do We Stand? Scandinavia Ballroom Andrea Cox, John Hopkins University, United States | |||||
4:25 pm - 4:45 pm | The Ebola Vaccine Experience: Cluster Randomisation and Implications for HCV Trial Design Scandinavia Ballroom John-Arne Røttingen, Norwegian Institute of Public Health, Norway | |||||
4:45 pm - 5:00 pm | Liver Or Die: A Peer Training Manual Scandinavia Ballroom Saga Rönnlund, Peer-educator for Liver or Die , The Swedish Drug Users Union | |||||
5:00 pm - 6:30 pm | Welcome Reception & Poster Viewing Session Foyer | |||||
6:30 pm | End of Conference Day 1 Scandinavia Ballroom |
08/09/2016 Treatment and Care | ||||||
9:00 am - 10:30 am | Session F: HCV Treatment Among PWID Scandinavia Ballroom Chairperson: Mags Maher, EuroNPUD, United Kingdom Chairperson: Julie Bruneau, Université de Montréal | |||||
9:00 am - 9:20 am | State-of-the-Art Lecture: Treatment of HCV Infection in 2016 Scandinavia Ballroom Graham Foster, University of London, United Kingdom | |||||
9:20 am - 9:40 am | HCV Treatment Trials Among PWID Scandinavia Ballroom Gregory Dore, The Kirby Institute, UNSW, Australia | |||||
9:40 am - 9:55 am | Community Supported HCV Treatment Model in Provision of Care for PWID in Ukraine Scandinavia Ballroom Sergii Filippovych, Treatment, Procurement and Supply management in Alliance for Public Health Abstract | |||||
9:55 am - 10:10 am | C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir (EBR) And Grazoprevir (GZR) in Persons Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT) Scandinavia Ballroom Olav Dalgard, Akershus University Hospital Abstract | |||||
10:10 am - 10:25 am | "I got my life back!" - Patients' experiences on being cured for hepatitis C. A qualitative study of fatigue and everyday life in a group of Danish patients. Oslo Nanette Braae Jensen, Department of Infectious Diseases, Odense University Hospital Abstract | |||||
10:25 am - 11:00 am | Coffee Break Foyer | |||||
11:00 am - 12:00 pm | Session G: Living with HCV Infection Scandinavia Ballroom Chairperson: Jude Byrne, The Australian Injecting and Illicit Drug users League Chairperson: Phillip Bruggmann | |||||
11:00 am - 11:10 am | Extrahepatic Manifestations of HCV Infection: Does HCV Cause Fatigue? Scandinavia Ballroom Olav Dalgard, Akershus University Hospital, Norway | |||||
11:10 am - 11:20 am | The Patient Perspective Scandinavia Ballroom Andi Hüttenmoser, Switzerland | |||||
11:20 am - 11:30 am | "But a spoon is not equipment": Risk Behaviour and Knowledge Seeking Among HCV-infected PWID Scandinavia Ballroom Aleksandra Bartoszko, Oslo and Akershus University College of Applied Social Sciences | |||||
11:30 am - 12:00 pm | Panel Debate: Should HCV treatment be prioritized for people with on-going injecting drug use? Scandinavia Ballroom Anne Øvrehus, University of Southern Denmark, Denmark Martin Kåberg, Karolinska Institutet, Sweden Sharon Hutchinson, Glasgow Caledonian University, United Kingdom Peer Brehm Christensen, University of Southern Denmark, Denmark Moderator: Graham Foster, University of London, United Kingdom | |||||
12:00 pm - 1:30 pm | Lunch Restaurant | |||||
12:15 pm - 1:15 pm | Industry Sponsored Symposium Stockholm/Oslo | |||||
1:45 pm - 3:00 pm | Session H: Oral Abstracts: Clinical København Chairperson: Georgios Zarkotos, Greek Drug Users Union, Greece Chairperson: Brian Conway, Vancouver ID Centre | Session I: Oral Abstracts: Social Sciences and Community Stockholm/Oslo Chairperson: Jo Neale, King's College London, United Kingdom | ||||
1:45 pm - 2:00 pm | Outreach Screening and Treatment for Hepatitis C in a Drug Treatment Unit – An Exploratory Assessment of Feasibility and Cost Effectiveness København Ashley Brown, Imperial College London Abstract | Relationships and Injecting Dyads: Identifying Key Interpersonal Factors Underlying Injecting Behaviors and Hepatitis C Virus (Hcv) Transmission among Injecting Partnerships Stockholm/Oslo Meghan Morris, University of California, San Francisco Abstract | ||||
2:00 pm - 2:15 pm | High Rates of Sustained Virological Response in People Who Inject Drugs Treated with All-Oral Direct Acting Antiviral Regimens København Alain Litwin, Albert Einstein College of Medicine and Montefiore Medical Center Abstract | Becoming a Buddy: Accordance and Incompatibility in the Hepatitis C Peer Support Role Stockholm/Oslo Magdalena Harris, London School of Hygiene and Tropical Medicine Abstract | ||||
2:15 pm - 2:30 pm | Real World Outcomes of Direct Acting Antiviral (DAA) Therapy for Hepatitis C (HCV) Amongst Persons Who Inject Drugs Treated in an Inner-city Hepatitis C treatment Program, Vancouver, Canada København Mark Hull, BC Centre for Excellence in HIV/AIDS Abstract Presentation | Qualitative Evaluation of the Decisions and Experiences of People Who Inject Drugs Who Received a Liver Disease Assessment as Part of a Liver Health Promotion Campaign: The Liverlife Study Stockholm/Oslo Alison Marshall, The Kirby Institute Abstract | ||||
2:30 pm - 2:45 pm | Comparison of Rates of Recurrent HCV Viremia in High-Risk Patients Receiving All-Oral and Interferon-Based Regimens København Tyler Raycraft Abstract | Qualitative Insights into the Lived Experience of Interferon-Free Treatments Stockholm/Oslo David Whiteley, Edinburgh Napier University Abstract | ||||
2:45 pm - 2:50 pm | Treatment Evaluation and Uptake among Persons with Chronic Hepatitis C on Opium Substitution Therapy. Is Treatment as Prevention Realistic? København Anne Lindebo Holm Øvrehus, Odense University Hospital Abstract | The Australian Response and Uptake of the New Subsidised Hepatitis C Direct Acting Anti-Virals among the Community of People Who Inject Drugs Stockholm/Oslo Jude Byrne, The Australian Injecting and Illicit Drug users League Abstract | ||||
2:50 pm - 2:55 pm | Optimal Adherence during HCV Treatment amongst Active Drug Users at a Community Based Program in Toronto, Canada København Kate Mason, South Riverdale Community Health Centre Abstract | Blood Borne Virus Risk Behaviours among People Who Inject Drugs in the UK: A Qualitative Exploration Stockholm/Oslo Davina Swan, King's College London Abstract | ||||
2:55 pm - 3:00 pm | Contingency Management Improves HCV Linkage and Treatment Outcomes in Persons Who Inject Drugs: A Pilot Study København Brianna Norton, Montefiore Medical Center Abstract | Utilising Social Capital to Promote HCV Treatment in Prison Stockholm/Oslo Lise Lafferty, The Kirby Institute, UNSW Australia Abstract | ||||
3:00 pm - 3:30 pm | Coffee Break Foyer | |||||
3:30 pm - 5:00 pm | Session J: Assessment and Management of HCV Infection Scandinavia Ballroom Chairperson: Jason Grebely, The Kirby Institute, UNSW, Australia | |||||
3:30 pm - 3:50 pm | Simplified HCV Diagnostics Scandinavia Ballroom Teri Roberts, Foundation for Innovative New Diagnostics, Switzerland | |||||
3:50 pm - 4:00 pm | It's Your Liver: Peer to Peer HCV Testing and Education Scandinavia Ballroom Bent Arild Stornes, ProLAR, Norway Abstract Presentation | |||||
4:00 pm - 4:20 pm | Liver Disease Assessment Among PWID: The Role of Transient Elastography Scandinavia Ballroom Peer Brehm Christensen, University of Southern Denmark, Denmark | |||||
4:20 pm - 4:40 pm | HCV Reinfection Following SVR: Clinical and Public Health Implications Scandinavia Ballroom Håvard Midgard, Akershus University Hospital, Norway | |||||
4:40 pm - 5:00 pm | Understanding Liver Cirrhosis and its Complications Scandinavia Ballroom John Willy Haukeland, Oslo University Hospital, Norway Abstract | |||||
5:00 pm | End of Conference Day 2 Scandinavia Ballroom | |||||
5:00 pm - 6:00 pm | INHSU General Assembly Members Meeting Scandinavia Ballroom | |||||
7:00 pm - 11:00 pm | Conference Dinner Posthallen |
09/09/2016 Access and Implementation | |||||||||||
8:30 am - 10:00 am | Session K: Parallel Workshops No location | ||||||||||
8:30 am - 10:00 am | Workshop #1: Getting Involved: Peer Support Skagerak Chairperson: Berne Stålenkrantz, The Swedish Drug Users Union, Sweden | Workshop #2: HCV Prevention: What Works and What Doesn’t? København Chairperson: Holly Hagan, New York University, United States Chairperson: Eberhard Schatz | Workshop #3: HCV Testing and Care in Prisons Eidsvoll Chairperson: Andrew Lloyd, University of New South Wales, Australia Chairperson: Pernille Sauer | Workshop #4: Liver Disease Assessment Among PWID: Hands On Stockholm Chairperson: Peer Brehm Christensen, University of Southern Denmark, Denmark Chairperson: Håvard Midgard, Akershus University Hospital, Norway | Workshop #5: The Low Threshold HCV Clinic Bergen Chairperson: John F Dillon, University of Dundee, United Kingdom Chairperson: Leon Wylie | Workshop #6: HCV Epidemiology: Populations, Data Sources and Missing Data Oslo Chairperson: Matthew Hickman, University of Bristol, United Kingdom Chairperson: Gregory Dore, The Kirby Institute, UNSW, Australia Chairperson: Julie Bruneau, Université de Montréal | |||||
10:00 am - 10:45 am | Coffee Break Foyer | ||||||||||
10:45 am - 12:00 pm | Session L: Novel Models of HCV Care Scandinavia Ballroom Chairperson: Gregory Dore, The Kirby Institute, UNSW, Australia | ||||||||||
10:45 am - 11:05 am | HCV Treatment in the Prison Setting Scandinavia Ballroom Andrew Lloyd, University of New South Wales, Australia Abstract | ||||||||||
11:05 am - 11:25 am | Pharmacy Based HCV Treatment Scandinavia Ballroom John F Dillon, University of Dundee, United Kingdom | ||||||||||
11:25 am - 11:40 am | Decentralised HCV Shared Care: The SACC Project Scandinavia Ballroom Lars Peters, Rigshospitalet, Denmark Abstract | ||||||||||
11:40 am - 12:00 pm | New Technologies for Addressing Treatment Barriers and Treatment Adherence Scandinavia Ballroom Jeffrey J Weiss, Mount Sinai Hospital, United States Abstract | ||||||||||
12:00 pm - 1:30 pm | Lunch Restaurant | ||||||||||
12:15 pm - 1:15 pm | Industry Sponsored Symposium Scandinavia Ballroom | ||||||||||
1:45 pm - 2:45 pm | Session M: Drug Policy Scandinavia Ballroom Chairperson: Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia Chairperson: Margaret Hellard, Burnet Institute, Australia | ||||||||||
1:45 pm - 2:05 pm | War on Drugs or War on Disease? Scandinavia Ballroom Ethan Nadelmann, Drug Policy Alliance, United States | ||||||||||
2:05 pm - 2:25 pm | Report from United Nations General Assembly Special Session on the World Drug Problem 2016 Scandinavia Ballroom Daniel Wolfe, Open Society Foundations, United States | ||||||||||
2:25 pm - 2:30 pm | HA-REACT: The European Joint Action on HIV and Coinfection Prevention and Harm Reduction - What's in it for Hepatitis? Scandinavia Ballroom Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark | ||||||||||
2:30 pm - 2:50 pm | Can information and communication technologies (ICTs) increase treatment opportunities for people who are homeless and people who inject drugs? Scandinavia Ballroom Jo Neale, King's College London, United Kingdom Abstract | ||||||||||
2:50 pm - 3:00 pm | The INHSU Video Project Scandinavia Ballroom Nikki Cavenagh, The Digital Clinic, Australia | ||||||||||
3:00 pm - 3:15 pm | Coffee Break Foyer | ||||||||||
3:15 pm - 4:00 pm | Session N: HCV Care in Resource-Limited Countries Scandinavia Ballroom Chairperson: Janko Belin, Društvo AREAL, Slovenia Chairperson: Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark | ||||||||||
3:15pm - 3:35 pm | The Georgia HCV Elimination Program Scandinavia Ballroom Maia Butsashvili, Health Research Union | ||||||||||
3:35 pm - 3:55 pm | Russia: Hepatitis C Treatment Gap and Ways Forward Scandinavia Ballroom Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia Abstract | ||||||||||
3:55 pm - 4:15 pm | Access to DAAs From an Asian Perspective Scandinavia Ballroom Giten Khwairakpam, TREAT Asia, Thailand | ||||||||||
4:15 pm - 4:25 pm | HCV Infection Among PWID: Research Priorities for Optimizing Prevention, Management and Treatment in the Era of DAAs Scandinavia Ballroom Jason Grebely, The Kirby Institute, UNSW, Australia | ||||||||||
4:25 pm - 4:30 pm | Conference Closing Scandinavia Ballroom | ||||||||||
4:30 pm | End of Conference Scandinavia Ballroom |